PL3541814T3 - 2-podstawione związki aminonaft[1,2-d]imidazol-5-onowe albo ich farmaceutycznie dopuszczalne sole - Google Patents
2-podstawione związki aminonaft[1,2-d]imidazol-5-onowe albo ich farmaceutycznie dopuszczalne soleInfo
- Publication number
- PL3541814T3 PL3541814T3 PL17817338T PL17817338T PL3541814T3 PL 3541814 T3 PL3541814 T3 PL 3541814T3 PL 17817338 T PL17817338 T PL 17817338T PL 17817338 T PL17817338 T PL 17817338T PL 3541814 T3 PL3541814 T3 PL 3541814T3
- Authority
- PL
- Poland
- Prior art keywords
- naphth
- imidazol
- compounds
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016222028 | 2016-11-15 | ||
JP2016250981A JP2018083799A (ja) | 2016-11-15 | 2016-12-26 | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
EP17817338.1A EP3541814B1 (en) | 2016-11-15 | 2017-11-15 | 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof |
PCT/US2017/061879 WO2018093957A1 (en) | 2016-11-15 | 2017-11-15 | 2-substituted amino-naphth[1,2-d]imidazol-5-one compounds or pharmaceutically acceptable salts thereof cross reference to related applications |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3541814T3 true PL3541814T3 (pl) | 2022-02-28 |
Family
ID=62237007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL17817338T PL3541814T3 (pl) | 2016-11-15 | 2017-11-15 | 2-podstawione związki aminonaft[1,2-d]imidazol-5-onowe albo ich farmaceutycznie dopuszczalne sole |
Country Status (9)
Country | Link |
---|---|
US (3) | US10738014B2 (pl) |
EP (2) | EP3971182A1 (pl) |
JP (3) | JP2018083799A (pl) |
CN (1) | CN110023311B (pl) |
CA (1) | CA3082764A1 (pl) |
ES (1) | ES2898836T3 (pl) |
HU (1) | HUE056922T2 (pl) |
PL (1) | PL3541814T3 (pl) |
PT (1) | PT3541814T (pl) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
RU2770091C2 (ru) | 2014-12-16 | 2022-04-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
CN113365616A (zh) | 2018-10-17 | 2021-09-07 | Ptc医疗公司 | 用于抑制和治疗α-突触核蛋白病、tau蛋白病及其他疾病的2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮 |
MX2022013856A (es) | 2020-05-13 | 2023-04-05 | Chdi Foundation Inc | Moduladores htt para tratar la enfermedad de huntington. |
JP7414020B2 (ja) | 2021-01-07 | 2024-01-16 | トヨタ自動車株式会社 | 自動駐車システム及び自動駐車システムの制御方法 |
JP2023536764A (ja) * | 2021-02-25 | 2023-08-29 | アプタバイオ セラピューティクス インコーポレイテッド | 新規なピラゾール誘導体 |
KR20240032997A (ko) | 2021-07-08 | 2024-03-12 | 피티씨 테라퓨틱스, 인크. | 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온을 포함하는 약제학적 조성물 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8605032D0 (en) * | 1986-02-28 | 1986-04-09 | Shell Int Research | Fungicides |
JPH01193253A (ja) * | 1988-01-29 | 1989-08-03 | Taisho Pharmaceut Co Ltd | 置換イミダゾール化合物 |
US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
JP4599292B2 (ja) | 2002-10-30 | 2010-12-15 | エジソン ファーマシューティカルズ, インコーポレイテッド | 物理的−化学的特性に基づく治療用化合物の同定 |
CA2580584C (en) | 2003-09-19 | 2015-07-28 | Galileo Pharmaceuticals, Inc. | Use of alpha-tocotrienol for treatment of mitochondrial diseases |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
ES2714900T3 (es) | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
WO2007035496A1 (en) | 2005-09-15 | 2007-03-29 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
CN101610782A (zh) | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有***或血小板生成素活性的化合物治疗呼吸链紊乱 |
EP3456707B1 (en) | 2007-11-06 | 2020-04-15 | PTC Therapeutics, Inc. | 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases |
CA2710253A1 (en) | 2008-01-07 | 2009-07-16 | Centocor Ortho Biotech Inc. | Method of treating erythropoietin hyporesponsive anemias |
US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
US20110046156A1 (en) | 2008-03-05 | 2011-02-24 | Miller Guy M | Treatment of hearing and balance impairments with redox-active therapeutics |
JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス疾患の処置のための2−置換−p−キノン誘導体 |
WO2009143268A2 (en) | 2008-05-22 | 2009-11-26 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
US8716486B2 (en) | 2008-06-25 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases |
US20100010100A1 (en) | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
WO2010014758A1 (en) | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress |
US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
DK2362875T3 (en) | 2008-10-28 | 2015-11-30 | Edison Pharmaceuticals Inc | METHOD OF PRODUCING ALPHA-tocotrienol AND DERIVATIVES |
WO2010126910A1 (en) | 2009-04-28 | 2010-11-04 | Edison Pharmaceuticals, Inc. | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
US20100273892A1 (en) | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
EP2609921A1 (en) | 2009-06-25 | 2013-07-03 | Ampere Life Sciences, Inc. | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
CN102647981B (zh) | 2009-08-26 | 2016-09-28 | 爱迪生制药有限公司 | 预防和治疗脑缺血的方法 |
US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
US20110263720A1 (en) | 2010-03-09 | 2011-10-27 | Penwest Pharmaceuticals Co. | Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
EA201201374A1 (ru) | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
MY183449A (en) | 2010-04-27 | 2021-02-18 | Bioelectron Tech Corp | Formulations of quinones for the treatment of ophthalmic diseases |
WO2012009271A1 (en) | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
JP6045494B2 (ja) | 2010-08-06 | 2016-12-14 | エジソン ファーマシューティカルズ, インコーポレイテッド | ナフトキノンによるミトコンドリア病の処置 |
WO2012068552A1 (en) | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
US20150057363A1 (en) | 2011-07-06 | 2015-02-26 | Guy M. Miller | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones |
US9162957B2 (en) | 2011-07-19 | 2015-10-20 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
US9629815B2 (en) | 2012-09-07 | 2017-04-25 | Bioelectron Technology Corporation | Benzoquinone derivatives for treating oxidative stress disorders |
JP6313791B2 (ja) | 2013-03-08 | 2018-04-18 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 皮膚科学的使用のためのレゾルシノール化合物 |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
EP2970158B1 (en) | 2013-03-15 | 2019-02-20 | BioElectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
EP3004071A1 (en) * | 2013-05-31 | 2016-04-13 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
CN112300078A (zh) * | 2013-12-30 | 2021-02-02 | 永进药品工业株式会社 | 1,2-萘醌的衍生物及其制备方法 |
CN109867647A (zh) * | 2014-02-07 | 2019-06-11 | 北京强新生物科技有限公司 | 3-取代的羰基萘并[2,3-b]呋喃衍生物或其药学上可接受的盐 |
RU2770091C2 (ru) | 2014-12-16 | 2022-04-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида |
JP2018500317A (ja) | 2014-12-16 | 2018-01-11 | バイオエレクトロン テクノロジー コーポレイション | トロロックスのキラル分割のための方法 |
JP2018502127A (ja) | 2015-01-12 | 2018-01-25 | バイオエレクトロン テクノロジー コーポレイション | 放射線被曝に対する防護のためのキノン |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
WO2017123823A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Alkyl-, acyl-, urea-, and aza-uracil sulfide:quinone oxidoreductase inhibitors |
WO2017123822A1 (en) | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels |
WO2018081644A1 (en) | 2016-10-28 | 2018-05-03 | Bioelectron Technology Corporation | Methods of analyzing p-hydroquinone levels and ratios |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
WO2018129411A1 (en) | 2017-01-06 | 2018-07-12 | Bioelectron Technology Corporation | Aryl- and heteroaryl-resorufin derivatives for treatment of oxidative stress disorders and liver and kidney disorders |
US20180333389A1 (en) | 2017-04-14 | 2018-11-22 | Bioelectron Technology Corporation | Vitamin e compositions and methods of use therefor |
-
2016
- 2016-12-26 JP JP2016250981A patent/JP2018083799A/ja active Pending
-
2017
- 2017-11-15 HU HUE17817338A patent/HUE056922T2/hu unknown
- 2017-11-15 JP JP2019524868A patent/JP7083826B2/ja active Active
- 2017-11-15 EP EP21202648.8A patent/EP3971182A1/en active Pending
- 2017-11-15 PL PL17817338T patent/PL3541814T3/pl unknown
- 2017-11-15 US US16/349,940 patent/US10738014B2/en active Active
- 2017-11-15 CA CA3082764A patent/CA3082764A1/en active Pending
- 2017-11-15 EP EP17817338.1A patent/EP3541814B1/en active Active
- 2017-11-15 CN CN201780070427.0A patent/CN110023311B/zh active Active
- 2017-11-15 ES ES17817338T patent/ES2898836T3/es active Active
- 2017-11-15 PT PT178173381T patent/PT3541814T/pt unknown
-
2020
- 2020-08-10 US US16/989,582 patent/US11390588B2/en active Active
-
2022
- 2022-06-01 JP JP2022089435A patent/JP2022107730A/ja not_active Withdrawn
- 2022-07-11 US US17/862,290 patent/US20230116786A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022107730A (ja) | 2022-07-22 |
JP7083826B2 (ja) | 2022-06-13 |
US20190330159A1 (en) | 2019-10-31 |
PT3541814T (pt) | 2021-11-05 |
US20230116786A1 (en) | 2023-04-13 |
CN110023311B (zh) | 2022-07-19 |
EP3971182A1 (en) | 2022-03-23 |
US10738014B2 (en) | 2020-08-11 |
ES2898836T3 (es) | 2022-03-09 |
EP3541814A1 (en) | 2019-09-25 |
EP3541814B1 (en) | 2021-10-20 |
US11390588B2 (en) | 2022-07-19 |
JP2018083799A (ja) | 2018-05-31 |
JP2019534310A (ja) | 2019-11-28 |
CA3082764A1 (en) | 2018-05-24 |
US20210061768A1 (en) | 2021-03-04 |
HUE056922T2 (hu) | 2022-03-28 |
CN110023311A (zh) | 2019-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3541814T3 (pl) | 2-podstawione związki aminonaft[1,2-d]imidazol-5-onowe albo ich farmaceutycznie dopuszczalne sole | |
ZA201700019B (en) | Substituted [1,2,4]triazole compounds | |
HUE052796T2 (hu) | Eljárás 4-ammónium-2,2,6,6-tetraalkilpiperidinil-sók elõállítására | |
EP3480198A4 (en) | NEW COMPOUND OR ITS PHARMACEUTICALLY ACCEPTED SALT | |
EP3102036A4 (en) | 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof | |
HK1258964A1 (zh) | 用於製備1,3-苯並間二氧雜環戊烯雜環化合物的方法 | |
EP3197275A4 (en) | 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal | |
ZA201708611B (en) | Pyrazole derivative, or pharmaceutically acceptable salt thereof | |
PL2949650T3 (pl) | Syntetyczny sposób otrzymywania 1,2-benzoizotiazolin-3-onu | |
ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
IL260011B (en) | History of water-soluble 5,3-diphenyldiazole compounds | |
HK1255014A1 (zh) | 製備取代5,6-二氫-6-苯基苯並[f]異喹啉-2-胺的方法 | |
SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
HK1254800A1 (zh) | 2,3,4,5-四氫吡啶-6-胺衍生物 | |
HK1251476A1 (zh) | 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽 | |
IL259073A (en) | History of abscisic acid - converted at the 3' position | |
PL3105243T3 (pl) | Pochodne 2',3'-dideoksy-5-fluorourydyny, sposób ich wytwarzania i zastosowanie | |
AU2017904453A0 (en) | Process for preparing 2-substituted 3',4'-polyhydroxystilbene compounds | |
HUP1400103A2 (en) | Compositions comprising nanostructured rosuvastatin, its pharmaceutically acceptable salts and cocrystals and process for the preparation |